Kala Pharmaceuticals, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The supplied filing is for Kala Pharmaceuticals, Inc.; it reports annual results, not separate fourth-quarter results.
Business context and strategy
Kala sold its commercial business, including EYSUVIS, INVELTYS and the AMPPLIFY delivery technology, to Alcon on July 8, 2022. It is now a clinical-stage ophthalmology company focused principally on KPI-012, an MSC secretome candidate for persistent corneal epithelial defects (PCED). The FDA accepted the IND in December 2022; the first patient in the U.S. CHASE Phase 2b trial was dosed in February 2023. The company also described KPI-014 as preclinical and said it had stopped non-MSC-S pipeline programs.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net product revenue | $3.9 million | $11.2 million |
| Cost of product revenue | $2.6 million | $4.1 million |
| Gross profit / margin on product revenue | $1.3 million / approximately 34% | $7.1 million / approximately 64% |
| Research and development expense | $17.7 million | $11.5 million |
| Selling, general and administrative expense | $65.0 million | $105.1 million |
| Loss from operations | $81.7 million | $130.2 million |
| Net loss | $44.8 million | $142.6 million |
| Cash used in operating activities | $78.9 million | $108.2 million |
Product revenue fell chiefly because the Alcon sale ended Kala’s commercial operations partway through the year. The 2022 gross margin is an annual, transition-year measure and is not necessarily indicative of future product economics. Net loss narrowed substantially, but included a $47.0 million net gain on the Alcon sale; the operating loss remained significant. Accumulated deficit was $587.2 million.
Cash and cash equivalents were $70.5 million at year-end, versus $92.1 million a year earlier. Total assets were $86.8 million and total liabilities $67.8 million; current assets were $85.9 million and current liabilities $25.7 million. Net cash decreased by $24.1 million, including $62.9 million of net sale proceeds from Alcon. The company reported $43.3 million of loan principal outstanding at year-end (carrying value $42.9 million); it paid down $9.3 million in January 2023, leaving approximately $34.0 million of principal. FY2022 interest expense was $7.3 million.
Material changes, outlook and risks
- Alcon paid $60.0 million upfront; Kala reported a $47.0 million net gain after transaction costs, transferred assets and deferred gain. Kala may receive up to $325 million in sales-based milestones, but none had been received by the filing date and payment depends on Alcon sales targets.
- A July 2022 workforce reduction eliminated 113 positions, including the entire commercial sales force. SG&A decreased year over year; management expected it to decrease further in 2023, while R&D was expected to rise as KPI-012 development advanced.
- Management estimated year-end cash would fund operations, debt service and capital needs into the first quarter of 2025, and expected it to cover safety and efficacy data from CHASE. It did not expect existing cash to fund completion of KPI-012 clinical development. Top-line CHASE data were targeted for Q1 2024; management said positive results, subject to regulatory discussions, could make the trial the first of two pivotal studies supporting a BLA.
- Kala remains loss-making, has no revenue-generating commercial products, and expects additional funding needs. Key risks include clinical and regulatory failure or delay, patient enrollment, third-party manufacturing and supply dependence, competition, uncertain Alcon milestones, and restrictive debt covenants. Nasdaq listing compliance is particularly important because a qualifying delisting could trigger debt default and acceleration.
- The December 2022 private placement generated approximately $31 million gross proceeds through common and Series E preferred stock. Each preferred share is initially convertible into 100 common shares, subject to ownership limits; the filing disclosed 5.3 million common shares issuable on conversion, creating substantial potential dilution. The transaction also gave investors specified participation, governance and consent rights.
- The company effected a 1-for-50 reverse stock split in October 2022. It reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor gave an unqualified opinion on the financial statements and did not provide an internal-control audit opinion.
Investor facts to verify
- Review CHASE enrollment, safety, endpoint execution and timing of results, and whether regulators agree the trial can serve as a pivotal study.
- Track cash burn, financing access, debt repayment dates and covenants, including continued Nasdaq listing compliance.
- Monitor Alcon product sales against milestone thresholds and confirm the status and recoverability of remaining inventory and related receivables.
- Assess potential dilution from Series E conversions, ATM sales, Combangio milestone shares or payments, and other equity issuances.
- Confirm KPI-012 manufacturing scale-up, supply redundancy and trial supply reliability, as well as the assumptions underlying management’s cash-runway estimate.